Proteogenomics reveals new target for beating drug resistanc

Doctors have nearly a dozen new targeted drugs to treat patients with acute myeloid leukemia, or AML, yet three of four patients still die within five years.

Related Keywords

Oregon , United States , American , Marina Gritsenko , Kevin Watanabe Smith , Paul Daisy Soros , Joshua Hansen , Karl Weitz , Tao Liu , Paul Piehowski , Jason Mcdermott , Elie Traer , Sunil Joshi , Sara Gosline , Kanupriya Agarwal , Cristina Tognon , James Pino , Chelsea Hutchinson , Jeff Tyner , Brian Druker , Michael Nestor , Karin Rodland , Knight Cancer Institute , Doe Pacific Northwest National Laboratory , National Cancer Institute , School Of Medicine , Blood Institute , Pacific Northwest Biomedical Innovation Co , Research Program , Alex Lemonade Stand Foundation , Department Of Energy Pacific Northwest National Laboratory , Druker Laboratory , Evansmds Foundation , American Cancer Society , Oregon Health Science University , Scholar Foundation , National Heart , Pacific Northwest National , Cell Reports Medicine , Pacific Northwest National Laboratory , Oregon Health , Knight Cancer , Annual Reviews , Camilo Posso , Jamie Moon , Chelsea Hutchinson Bunch , Nicola Long , Cancer Clinical Proteomics Research , Daisy Soros Fellowship , Lemonade Stand , Cancer , Acute Myeloid Leukemia , Flood , Rain , Fell , Drugs , Genes , Laboratory , Leukemia , Machine Learning , Medicine , Myeloid Leukemia , Protein , Roteomics , Research , Humor ,